CPC Scientific
Sunnyvale, CA
Program data pending ClinicalTrials.gov matching
—
Not Assessed
○ FDA Inspections
○ Clinical Trials
○ SEC Filings
✓ Press (2)
Signal Score & Pillar Breakdown
Quality Compliance
—
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations
—
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs
— no verified data
Sponsors— no verified data
ModalitiesPeptide API (SPPS), GLP-1 APIs, Custom Peptide API, Semaglutide API
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Data sourced from ClinicalTrials.gov, FDA, SEC EDGAR, and verified press only. No unverified estimates shown.
Financial Stability
—
Insufficient financial data. Score requires company profile or SEC filings.
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity
—
Insufficient capacity data. Score requires company profile with manufacturing site information.
Recent Press2 articles
Broad modality coverage (4 modalities)
Recent News 2 articles
Peptide CDMO (Pharmaceutical) Market Size Outlook with Competitive Analysis 2026 to 2035 - openPR.com
Cell Penetrating Peptide Market Forecast to Reach $8.12 Billion by 2033 | Astute Analytica - GlobeNewswire
Represent this organization? Contact us to verify or update this profile.